Adamas Pharmaceuticals plans $25 million at-the-market equity offering

Deal arranged with Cantor Fitzgerald; proceeds fund corporate purposes

By Devika Patel

Knoxville, Tenn., June 2 – Adamas Pharmaceuticals, Inc. negotiated a $25 million at-the-market equity offering with agent Cantor Fitzgerald & Co., according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission.

The common stock will be sold on a best-efforts basis through commercially reasonable efforts.

Cantor will be paid a 3% commission.

Proceeds will be used for working capital and other general corporate purposes.

The pharmaceutical company is based in Emeryville, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.